TCGA-KU-A66T-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.280
- G2M_CHECKPOINT+0.250
- SPERMATOGENESIS+0.240
- GLYCOLYSIS+0.210
- PROTEIN_SECRETION+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.190
- HYPOXIA+0.180
- KRAS_SIGNALING_DN+0.160
- MYC_TARGETS_V1+0.150
- PANCREAS_BETA_CELLS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.300
- MYC_TARGETS_V2-0.300
- MYOGENESIS-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- APICAL_SURFACE-0.250
- COMPLEMENT-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R360 | — | — | 0.770 |
| 2 | C3N-04180 | — | cohortA3 | 0.768 |
| 3 | TCGA-E9-A1RC-01A-11R-A157-07 | — | B | 0.762 |
| 4 | R259 | — | — | 0.758 |
| 5 | SRR25617914 | — | C | 0.755 |
| 6 | ERR2278878 | — | — | 0.752 |
| 7 | 3f4020bf-9f9a-479d-b3af-883c5875d84e | — | — | 0.752 |
| 8 | MNG446 | — | — | 0.748 |
| 9 | SRR8518274 | — | C | 0.745 |
| 10 | X7635bae0.a49b.4c58.ae88.de85f60b4ab6 | — | cohortA3 | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |